William Pedranti, JD

William Pedranti, JD - Adviser / Chief Operating Officer of SCILEX

Adviser / Chief Operating Officer of SCILEX

William Pedranti is President of Pedranti Law Group, PC. In the past, in addition to serving as partner at national law firms, Will was the Vice President, General Counsel and member of the Executive Committee of a publicly traded, commercial-stage biotech company that operated globally. He had oversight over all legal operations of the company, including corporate governance, SEC, compliance, regulatory, business development, litigation/disputes, securities and intellectual property functions. Will has gained unique industry insight from his many years of experience serving both in-house as well as an outside advisor to numerous life science companies.

Throughout his career, Will has had extensive experience performing general company representation for both public and private companies, including providing day-to-day legal advice on all aspects of operation and business strategy, as well as attending board of directors and board committee meetings and providing advice to the board on various topics including corporate governance.

Will has also provided counsel regarding compliance with SEC and Nasdaq corporate governance standards including the drafting and filing of periodic securities and regulatory reports.

Additionally, he has represented companies in various types of M&A as well as other business transactions (both U.S. and international) that have included co-promotion, licensing, clinical study, employment, IT, consulting and confidentiality agreements. Will has represented companies in securities offerings including structuring, drafting and negotiating securities purchase agreements, registration right agreements, certificates of designation, warrants and legal opinions.

Will was the chief compliance officer for a biotech company where he oversaw the company’s compliance efforts across multiple disciplines, including providing compliance training, and investigating and resolving compliance matters. He also advised the corporation on FDA regulatory matters.

Back to Leadership